Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;209(1):139-146.
doi: 10.1007/s10549-024-07480-x. Epub 2024 Sep 16.

Regional differences in neo/adjuvant chemotherapy timing in patients with early-stage triple-negative breast cancer in England

Laaeba Mirza #  1 , Luke Steventon #  2   3 , Rebecca Roylance  3   4 , Chantelle Hughes  3 , Chiara Creed  3 , Emma Morris  3 , Ian Purcell  5 , Suzanne Frank  6 , Neil Masters  7 , Pinkie Chambers  2   3
Affiliations

Regional differences in neo/adjuvant chemotherapy timing in patients with early-stage triple-negative breast cancer in England

Laaeba Mirza et al. Breast Cancer Res Treat. 2025 Jan.

Abstract

Purpose: Triple-negative breast cancer (TNBC) is an aggressive breast cancer histological type that is predictive of poor outcomes, shorter remission periods and reduced survival. TNBC is treated with surgery and neo/adjuvant chemotherapy, with evidence of association between longer periods from surgery to adjuvant chemotherapy (time to chemotherapy, TTC) and poorer survival outcomes. This study investigated regional differences in TTC period between regions and ethnic groups to evaluate equity of care in the English TNBC population. Time from neoadjuvant chemotherapy to surgery (time to surgery, TTS) was also compared between groups.

Methods: This retrospective cohort study compared TTC and TTS periods in TNBC patients in England over a two-year period. TTC and TTS were compared by English region and ethnicity, testing for significant differences in treatment pathway timing by these demographics.

Results: 1347 TNBC patients were included in the study. Significant regional differences in TTC were observed, with the longest median period of 50 days (IQR 36, 83) in the Midlands compared to 38 days (IQR 27, 55) in the North West (p < 0.001). No significant differences in TTS were observed between regions. Ethnicity was not significantly associated with timeliness of neo/adjuvant chemotherapy initiation (p > 0.05).

Conclusion: These findings suggest regional differences in TTC for patients treated with surgery and chemotherapy for TNBC. Given evidence of increased mortality risk as the TTC period increases, the causes of regional disparities warrant further investigation. This study can inform targets for improvement in the delivery of adjuvant chemotherapy in cancer treatment centres in England.

Keywords: Breast; Cancer; Chemotherapy; Delay; Surgery; Triple-negative.

PubMed Disclaimer

Conflict of interest statement

Declarations. NM reports honoraria from Gilead, Novartis and Roche. SF reports honoraria from Astra Zeneca, Chugai, Gilead, Lilly, Novartis, Pfizer, Roche & Seagen. EM reports honoraria from Lilly and Celltrion. IP reports honoraria from Novartis and educational sponsorship from Roche, Novartis and Pfizer. CC reports sponsorship from Gilead, B. Braun and Novartis. PC reports grant funding from the National Institute for Health and Care Research LS, LM, RR, EM and CH report no disclosures/conflicts of interest.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clinic 71(3):209–249
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33 - DOI - PubMed
    1. The Global Cancer Observatory. united-kingdom-fact-sheets: World Health Organisation; 2021 [ https://gco.iarc.fr/today/data/factsheets/populations/826-united-kingdom... .
    1. Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17(3):173–176 - DOI - PubMed
    1. De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F et al (2007) High-dose chemotherapy for triple negative breast cancer. Ann Oncol 18(1):202–203 - DOI - PubMed

LinkOut - more resources